Faculty Profiles - HIRAI Youji

Papers - HIRAI Youji

Division display 1 - 20 of about 95 ／ All the affair displays >>

Monokine induced by gamma interferon levels in plasma might be a diagnostic marker of Hydroa vaccniforme lymphoproliferative disorder systemic form. International journal

Tomoko Miyake, Takenobu Yamamoto, Yoji Hirai, Takahide Takahashi, Takuya Furuhashi, Hisashi Nomura, Yoshio Kawakami, Shin Morizane

Journal of the American Academy of Dermatology 2024.11

A case of anaphylaxis to kumquat (Citrus japonica). International journal

Shogo Ikezawa, Emi Yokoyama, Hitoshi Urakami, Mikiko Takigawa, Tomoko Miyake, Yoji Hirai, Yoshio Kawakami, Shin Morizane

European journal of dermatology : EJD 34 ( 5 ) 539 - 541 2024.10

The treatment effect of endovascular therapy for chronic limb-threatening ischemia with systemic sclerosis. International journal

Yoshihiro Matsuda, Tomoko Miyake, Hironobu Toda, Kota Tachibana, Hayato Nomura, Yoji Hirai, Yoshio Kawakami, Naoya Sakoda, Shin Morizane

The Journal of dermatology 51 ( 8 ) 1108 - 1112 2024.8

Language：English Publishing type：Research paper (scientific journal)

Systemic sclerosis (SSc) is a collagen disease with immune abnormalities, vasculopathy, and fibrosis. Ca blockers and prostaglandins are used to treat peripheral circulatory disturbances. Chronic limb-threatening ischemia (CLTI) is a disease characterized by extremity ulcers, necrosis, and pain due to limb ischemia. Since only a few patients present with coexistence of CLTI and SSc, the treatment outcomes of revascularization in these cases are unknown. In this study, we evaluated the clinical characteristics and treatment outcomes of seven patients with CLTI and SSc, and 35 patients with uncomplicated CLTI who were hospitalized from 2012 to 2022. A higher proportion of patients with uncomplicated CLTI had diabetes and male. There were no significant differences in the age at which ischemic ulceration occurred, other comorbidities, or in treatments, including antimicrobial agents, revascularization and amputation, improvement of pain, and the survival time from ulcer onset between the two subgroups. EVT or amputation was performed in six or two of the seven patients with CLTI and SSc, respectively. Among those who underwent EVT, 33% (2/6) achieved epithelialization and 67% (4/6) experienced pain relief. These results suggest that the revascularization in cases with CLTI and SSc should consider factors such as infection and general condition, since revascularization improve the pain of these patients.

DOI： 10.1111/1346-8138.17334

PubMed

researchmap

Acquired generalized anhidrosis following durvalumab treatment in a patient with advanced non-small cell lung cancer. International journal

Yuko Fujimoto, Yoshio Kawakami, Tomoko Miyake, Yoji Hirai, Masahiro Tabata, Shin Morizane

The Journal of dermatology 2024.7

Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma. International journal

Yoji Hirai, Jun Sakurai, Shiho Yoshida, Takashi Kikuchi, Toshiharu Mitsuhashi, Tomoko Miyake, Taku Fujimura, Riichiro Abe, Hiroki Fujikawa, Hikari Boki, Hiraku Suga, Sayaka Shibata, Tomomitsu Miyagaki, Takatoshi Shimauchi, Eiji Kiyohara, Yoshio Kawakami, Shin Morizane

The Journal of dermatology 51 ( 8 ) 1037 - 1049 2024.6

Language：English Publishing type：Research paper (scientific journal)

Brentuximab vedotin (BV), a conjugate of anti-CD30 antibody and monomethyl auristatin E, has emerged as a promising treatment option for refractory CD30+ mycosis fungoides (MF) and primary cutaneous anaplastic large-cell lymphoma (pcALCL). BV has been shown to be safe and effective in treating Hodgkin's lymphoma and peripheral T-cell lymphoma. This multicenter, prospective, single-arm phase I/II study evaluated the efficacy of BV in Japanese patients with CD30+ cutaneous lymphomas, namely CD30+ cutaneous T-cell lymphoma. Participants were divided into two groups: those with CD30+ MF or pcALCL (cohort 1, n = 13) and those with CD30+ lymphoproliferative disorders other than those in cohort 1 (cohort 2, n = 3). The studied population included the full analysis set (FAS), modified FAS (mFAS), and safety analysis set (SAF). These sets were identified in cohorts 1 and 1 + 2 and labeled FAS1 and FAS2, mFAS1 and mFAS2, and SAF1 and SAF2, respectively. Each treatment cycle lasted 3 weeks, and BV was continued for up to 16 cycles after the third cycle based on treatment response. The primary endpoint was the 4-month objective response rate (ORR4) determined by the Independent Review Forum (IRF). ORR4 was 69.2% for FAS1 and 62.5% for FAS2 (P < 0.0001). Secondary endpoints of ORR, assessed using the global response score (53.8% in FAS1) and modified severity-weighted assessment tool (62.5% in FAS1), using the IRF, provided results comparable to the primary findings. The incidence of ≥grade 3 adverse events (≥15%) in SAF1 was peripheral neuropathy in three patients (23%) and fever and eosinophilia in two patients (15%). In conclusion, BV showed favorable efficacy, tolerability, and safety profile in Japanese patients with relapsed or refractory CD30+ primary cutaneous T-cell lymphoma. The trial was registered with University Hospital Medical Information Network Clinical Trials Registry, Japan (protocol ID: UMIN000034205).

DOI： 10.1111/1346-8138.17324

PubMed

researchmap

Disseminated Lomentospora prolificans infection presenting with multiple cutaneous lesions in an immunocompromised host: A case report and literature review. International journal

Masaya Kawamoto, Yoshio Kawakami, Yoji Hirai, Saya Kubota, Hideaki Fujiwara, Yayoi Ueda, Kazushi Anzawa, Yoshinobu Maeda, Shin Morizane

The Journal of dermatology 51 ( 11 ) e402-e403 2024.6

Bexarotene-induced hypothyroidism and dyslipidemia; a nation-wide study.

Katsunori Manaka, Junichiro Sato, Yusuke Hikima, Hirofumi Horikoshi, Maho Taguchi, Akimichi Morita, Hiraku Suga, Hikari Boki, Taku Fujimura, Yoji Hirai, Takatoshi Shimauchi, Chiharu Tateishi, Eiji Kiyohara, Ikko Muto, Hideki Nakajima, Riichiro Abe, Kazuyasu Fujii, Chikako Nishigori, Eiji Nakano, Kentaro Yonekura, Takeru Funakoshi, Masahiro Amano, Tomomitsu Miyagaki, Reiko Yamashita, Makoto Sugaya, Toshihisa Hamada, Masaomi Nangaku, Taroh Iiri, Noriko Makita

Endocrine journal 71 ( 8 ) 777 - 787 2024.6

Language：English Publishing type：Research paper (scientific journal)

Central hypothyroidism and dyslipidemia are well-known adverse events (AEs) of bexarotene therapy. Although hypothyroidism is known to cause dyslipidemia, no study has examined the association between hypothyroidism and dyslipidemia in patients undergoing bexarotene therapy. The aim of this study is to examine this association. A retrospective observational study was performed among 294 patients who initiated bexarotene therapy in Japan (nation-wide postmarketing complete surveillance). Jonckheere-Terpstra (one sided) test was performed to evaluate the effect of the bexarotene dose on lipid metabolisms, and regression analyses were performed to evaluate associations of bexarotene dose, free thyroxine (FT4), body mass index (BMI), and lipid metabolisms. Most patients developed hypothyroidism. Two-third of patients showed FT4 values below the lower limit at 1 week. Triglycerides (TG) increased in a bexarotene dose-dependent manner, and grade ≥3 AEs on hypertriglyceridemia was observed in 39% of the patients. Additionally, one-third of grade ≥3 AEs on hypertriglyceridemia occurred within 1 week. The delta_FT4 (difference in FT4 from baseline) negatively correlated with TG increase at 1 week (p = 0.012) but not with low density lipoprotein cholesterol (LDL-C) increase at any week. Bexarotene-induced hypothyroidism is almost inevitable and occurred quickly. Bexarotene-induced hypertriglyceridemia showed positive bexarotene dose dependency and negative delta_FT4 dependency. Prophylactic and appropriate thyroid hormone compensation therapy and starting bexarotene at low doses with subsequent titration while managing dyslipidemia may have a beneficial effect for the successful continuation of bexarotene therapy without severe endocrine and metabolic AEs.

DOI： 10.1507/endocrj.EJ23-0699

PubMed

researchmap

Pruritic folliculitis of pregnancy with granular deposition of immunoglobulin G along the basement membrane zone. International journal

Mana Usui-Taniguchi, Yoshio Kawakami, Yoichiro Toi, Tatsuya Kaji, Yoshiko Matsuura, Emi Yokoyama, Tomoko Miyake, Yoji Hirai, Shin Morizane

The Journal of dermatology 51 ( 4 ) e125-e126 2023.11

Successful treatment with secukinumab in a patient with generalized pustular psoriasis preceded by palmoplantar lesions. International journal

Nozomi Sawai, Yoshio Kawakami, Kota Tachibana, Hayato Nomura, Tomoko Miyake, Emi Yokoyama, Yoji Hirai, Shin Morizane

The Journal of dermatology 50 ( 12 ) e413-e414 2023.8

Prognostic factors for primary cutaneous anaplastic large cell lymphoma: a multicenter retrospective study from Japan. International journal

Tomomitsu Miyagaki, Norihito Inoue, Hiroaki Kamijo, Hikari Boki, Naomi Takahashi-Shishido, Hiraku Suga, Takatoshi Shimauchi, Eiji Kiyohara, Yoji Hirai, Kentaro Yonekura, Kengo Takeuchi, Makoto Sugaya

The British journal of dermatology 189 ( 5 ) 612 - 620 2023.8

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Clinical implications of DUSP22 rearrangement and the association between DUSP22 rearrangement and lymphoid enhancer-binding factor 1 (LEF1) expression pattern in CD30-positive cutaneous T-cell lymphomas (CTCLs) are unknown. OBJECTIVES: This study assessed the incidence of DUSP22 rearrangement and its clinical and immunohistochemical implications in primary cutaneous anaplastic large cell lymphoma (pcALCL), lymphomatoid papulosis (LyP), and CD30-positive mycosis fungoides (MF) with large cell transformation (MF-LCT), especially focusing on the association with the prognosis and LEF1 expression pattern. Prognostic factors of pcALCL were also examined. METHODS: Multicenter retrospective study including patients with pcALCL, LyP, and MF-LCT diagnosed between January 1, 2000 and December 31, 2018 in Japan. Baseline data at diagnosis, treatment course, overall survival (OS), and disease-specific survival (DSS) were collected. Immunohistochemical analysis and fluorescence in situ hybridization to detect DUSP22 and TP63 rearrangement were performed using skin samples at diagnosis. We investigated the association between staining pattern and these gene rearrangements. We also assessed the prognostic implications of clinical status, immunohistochemical results and the presence of gene rearrangements. RESULTS: DUSP22 rearrangement was detected in 50% of pcALCL cases (11/22), but not in any cases with LyP (0/14) or MF-LCT (0/11). TP63 rearrangement was not detected in any case. Clinically, pcALCL patients with DUSP22 rearrangement did not tend to form ulcers (p = 0.081). There was no significant association between DUSP22 rearrangement status and immunohistochemical results including LEF1 expression pattern. T3 stage and the presence of lower limb lesions were significantly associated with shorter OS (p = 0.012 and 0.021, respectively by log-rank test). Similarly, they were significantly correlated with shorter DSS (p = 0.016 and 0.0001, respectively). CONCLUSION: DUSP22 rearrangement is relatively specific to pcALCL among CD30-positive CTCLs in Japan. Although LEF1 expression pattern was not related with DUSP22 rearrangement in pcALCL, there was no rearrangement if LEF1 was not expressed. We confirmed that T3 stage and the lower limb involvement were significantly associated with the decreased OS and DSS. Presence or absence of lower limb lesions should better be included in T stage subcategory in the future.

DOI： 10.1093/bjd/ljad266

PubMed

researchmap

Angioedema‐like eyelid edema following the second NVX‐CoV2373 <scp>COVID</scp>‐19 vaccination

Mari Matsumoto, Yoshio Kawakami, Tomoko Miyake, Yoji Hirai, Hitomi Kataoka, Fumio Otsuka, Shin Morizane

Journal of Cutaneous Immunology and Allergy 6 ( 5 ) 194 - 195 2023.7

BNT162b2 mRNA COVID-19ワクチン接種後に発症したacute diffuse and total alopecia of the female scalpの1例

川本雅也, 川上佳夫, 松田吉弘, 平井陽至, 森実真, 多田讓治

日本皮膚科学会雑誌 133 ( 8 ) 1891 - 1891 2023.7

Coexpression of natural killer cell antigens by T-cell large granular lymphocytes in hydroa vacciniforme lymphoproliferative disorder and the involvement of Vδ1 + epithelial-type γδT cells.

Yoji Hirai, Keiji Iwatsuki, Takahide Takahashi, Tomoko Miyake, Yuki Nakagawa, Shogo Tanimoto, Yoshio Kawakami, Shin Morizane

International journal of hematology 118 ( 1 ) 54 - 64 2023.7

Language：English Publishing type：Research paper (scientific journal)

Hydroa vacciniforme lymphoproliferative disorder (HV-LPD) is a cutaneous variant of chronic active Epstein-Barr virus disease. We examined the coexpression of T- and natural killer (NK)-cell antigens in five patients with classic HV (cHV) and five with systemic HV (sHV). T-cell receptor (TCR) repertoire analysis was performed with high‑throughput sequencing. All five cHV patients had increased γδT cells (> 5%), whereas five sHV patients showed γδT- and αβT-cell dominance in two patients each, and a mixture of abnormal γδT and αβT cells in one. Circulating CD3 + T cells expressed CD16/CD56 at 7.8-42.3% and 1.1-9.7% in sHV and cHV, respectively. The percentage of CD16/CD56 + T cells was higher in the large granular lymphocyte or atypical T-cell fractions in sHV, but no TCR Vα24 invariant chain characteristic of NKT cells was detected. Considerable numbers of CD3 + cells expressing CD56 were observed in sHV skin infiltrates. Of the circulating γδT cells tested, TCR Vδ1 + cells characteristic of the epithelial type of γδT cells were dominant in two sHV cases. Thus, atypical αβT and γδT cells in HV-LPD can express NK-cell antigens, such as CD16 and CD56, and Vδ1 + epithelial-type γδT cells are a major cell type in some HV-LPD cases.

DOI： 10.1007/s12185-023-03599-7

PubMed

researchmap

ダブラフェニブ・トラメチニブ内服中にサルコイド様皮疹を呈した悪性黒色腫の1例

別木祐介, 神野泰輔, 立花宏太, 三宅智子, 平井陽至, 川上佳夫, 森実真

日本皮膚科学会雑誌 133 ( 8 ) 1894 - 1894 2023.7

Diagnostic and disease severity determination criteria for hydroa vacciniforme lymphoproliferative disorders and severe mosquito bite allergy International journal

Yoji Hirai, Hideo Asada, Toshihisa Hamada, Jun‐ichi Kawada, Hiroshi Kimura, Ayako Arai, Koichi Ohshima, Shouichi Ohga, Keiji Iwatsuki

The Journal of Dermatology 50 ( 7 ) e198-e205 2023.5

Language：English Publishing type：Research paper (scientific journal) Publisher：Wiley

Hydroa vacciniforme lymphoproliferative disorder (HV-LPD) and severe mosquito bite allergy (SMBA) are both cutaneous forms of Epstein-Barr virus (EBV)-associated T/natural killer (NK) cell LPDs and are closely related to chronic active EBV disease (CAEBV) and EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH). HV-LPD is further divided into classic HV, a benign subtype mediated by EBV-positive γδT cells, and systemic HV, another life-threatening subtype mainly associated with EBV-positive αβT or γδT cells. The vast majority of patients with SMBA have increased numbers of EBV-infected NK cells in the blood. Clinical symptoms of HV-LPD and SMBA often overlap in the same patient and may progress to more serious disease conditions equivalent to the systemic form of CAEBV. To define the disease spectrum of HV-LPD and SMBA, we propose the diagnostic criteria and the determination criteria for disease severity. The proposed diagnostic criteria are consistent with those for CAEBV and EBV-HLH in the guidelines for the management for CAEBV and related disorders 2023.

DOI： 10.1111/1346-8138.16842

PubMed

researchmap

ラズベリーによるアナフィラキシーの1例

赤松由規, 川上佳夫, 藤田周作, 川本友子, 三宅智子, 平井陽至, 森実真

日本臨床皮膚科医会雑誌 40 ( 3 ) 465 - 465 2023.5

当院における強皮症合併重症下肢虚血7例の臨床学的検討

松田吉弘, 三宅智子, 戸田洋伸, 立花宏太, 野村隼人, 平井陽至, 川上佳夫, 迫田直也, 廣田真規, 森実真

日本皮膚科学会雑誌 133 ( 5 ) 1361 - 1361 2023.5

初診時,手足口病様皮疹を呈した新生児水疱性類天疱瘡の1例

別木祐介, 徳田真優, 前琴絵, 妹尾春佳, 立花宏太, 三宅智子, 平井陽至, 川上佳夫, 森実真, 宇田和宏, 斎藤友希恵, 茂原研司, 津下充, 八代将登

日本皮膚科学会雑誌 133 ( 4 ) 715 - 715 2023.4

セクキヌマブが奏功した掌蹠膿疱症を背景とする膿疱性乾癬の1例

澤井希望, 川上佳夫, 徳田真優, 廣瀬梓, 別木祐介, 高須賀琴巳, 篠倉美里, 立花宏太, 横山恵美, 三宅智子, 平井陽至, 森実真, 多田譲治

日本皮膚科学会雑誌 133 ( 3 ) 524 - 524 2023.3

CD8+αβT細胞優位型種痘様水疱症リンパ増殖異常症の1例

大林三裕佳, 中村賢人, 古橋卓也, 岩月啓氏, 三宅智子, 平井陽至, 谷田けい, 金兼弘和, 西田徹也, 木村宏, 森田明理

皮膚科の臨床 65 ( 2 ) 273 - 278 2023.2

Language：Japanese Publisher：金原出版(株)

＜文献概要＞26歳,女性。21歳夏頃より頭部,顔面,頸部,上背部に痂皮を伴う丘疹と水疱が出現した。ざ瘡,毛包炎の治療は無効であり,ステロイド外用中も再燃を繰り返した。経過中に発熱も伴うようになり,口唇や顔面が一時的に腫脹することもあった。病変部および末梢血中のEpstein-Barr virus感染細胞の存在を証明し,種痘様水疱症リンパ増殖異常症と診断した。フローサイトメトリーでは,CD8+αβT細胞に優位にEpstein-Barr virus感染があり,成人発症で全身症状を伴う点からも予後不良である可能性が懸念される。現状他臓器障害はなく,Epstein-Barr virus感染細胞数も比較的少数であるが,今後も注意深い観察を行い,造血幹細胞移植の必要性とタイミングについて検討を要する。

researchmap

Other Link： https://search.jamas.or.jp/default/link?pub_year=2023&ichushi_jid=J01266&link_issn=&doc_id=20230217120032&doc_link_id=10.18888%2Fhi.0000003782&url=https%3A%2F%2Fdoi.org%2F10.18888%2Fhi.0000003782&type=%E5%8C%BB%E6%9B%B8.jp_%E3%82%AA%E3%83%BC%E3%83%AB%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

　 PREV - NEXT 　

< HIRAI Youji >

Papers - HIRAI Youji